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RESEARCH
Virus-like vaccines against HIV/SIV synergize 
with a subdominant antigen T cell vaccine
Melanie Schwerdtfeger1,2* , Anne‑Marie Carola Andersson1,3, Lasse Neukirch1,4 and Peter Johannes Holst1,3
Abstract 
Background: In non‑human primates (NHPs) and humans, partial protection from HIV/SIV infection or suppression 
of replication is achievable by Env‑binding antibodies and Gag‑specific CD8+ T‑cells targeting protective epitopes. 
Unfortunately, such T‑cell responses are frequently dominated by responses to non‑protective, variable epitopes. In 
this study we attempt to combine three independent approaches, each developed to prevent immunodominance of 
non‑protective epitopes. These approaches were (1) vaccines consisting exclusively of putatively protective p24 Gag 
highly conserved elements (CEs), (2) vaccines using solely subdominant antigens which were acutely protective in a 
recent NHP trial, and (3) virus‑encoded virus‑like particle vaccines (virus‑like vaccines/VLVs) using heterologous Env 
and Gag sequences to enable selection of broadly cross‑reactive responses and to avoid immunodominance of non‑
conserved sequences in prime‑boost regimens as previously observed.
Methods: We vaccinated outbred CD1 mice with HIV‑1 clade B Gag/Env encoded in an adenoviral prime and 
SIVmac239 Gag/Env in an MVA boost. We combined this completely heterologous immunization regimen and the 
homologous SIVmac239 Gag/Env immunization regimen with an additional prime encoding SIV CEs and accessory 
antigens Rev, Vif and Vpr (Ad‑Ii‑SIVCErvv). T‑cell responses were analyzed by intracellular cytokine staining of spleno‑
cytes and antibody responses by trimer‑specific ELISA, avidity and isotype‑specific ELISA.
Results: Env dominance could be avoided successfully in the completely heterologous prime‑boost regimen, but 
Env immunodominance reappeared when Ad‑Ii‑SIVCErvv was added to the prime. This regimen did however still 
induce more cross‑reactive Gag‑specific CD8+ T‑cells and Env‑specific antibodies. Including Ad‑Ii‑SIVCErvv in the 
homologous prime‑boost not only elicited accessory antigen‑specific CD8+ memory T‑cells, but also significantly 
increased the ratio of Gag‑ to Env‑specific CD8+ T‑cells. The CD4+ T‑cell response shifted away from structural anti‑
gens previously associated with infection‑enhancement.
Conclusion: The homologous Gag/Env prime‑boost with Ad‑Ii‑SIVCErvv prime combined acutely protective CD8+ 
T‑cell responses to subdominant antigens and Env‑binding antibodies with chronically protective Gag‑specific CD8+ 
T‑cells in outbred mice. This vaccine regimen should be tested in an NHP efficacy trial.
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Background
The primary goal of a human immunodeficiency virus 
type 1 (HIV-1) vaccine is to protect from HIV-1 acqui-
sition [1]. The partial protection in the HIV vaccination 
trial RV144 correlated with IgG antibodies targeting 
the V1V2 regions of the viral envelope (Env) protein [2, 
3]. If prevention of infection is not possible an alterna-
tive goal is to induce CD8+ T-cells that can control the 
infection [1]. In chronically infected individuals CD8+ 
T-cells targeting group-specific antigen (Gag) correlated 
directly with a lower viral load while Env-specific CD8+ 
T-cells correlated inversely [4, 5]. These associations pro-
vide an incentive to increase antibody responses towards 
Env as well as CD8+ T-cell responses towards Gag and to 
reduce Env-specific CD8+ T-cell responses.
A great impediment for the development of an HIV-1 
vaccine that induces protective immune responses or 
such that can control HIV-1 infection is the immuno-
dominance of non-protective, variable epitopes which the 
virus can easily mutate without fitness cost. An immune 
response towards these epitopes suppresses responses 
towards more conserved regions with a higher protec-
tive potential [6]. Kulkarni et al. addressed this problem 
by designing immunogens based on 7  highly conserved 
elements (CEs) in HIV-1 p24 Gag [7]. A DNA vaccine 
encoding this string of peptides raised higher T-cell 
responses to the CEs compared to vaccination with full-
length Gag DNA in mice and macaques [7, 8]. A prime 
vaccination using CE DNA, followed by a boost with full-
length Gag DNA, increased the magnitude and breadth 
of Gag-specific T-cell responses, including responses to 
the CEs [8]. In Hu et al. simian immunodeficiency virus 
(SIV) p27 Gag CEs were described in the same positions 
as the HIV-1 p24 CEs [9]. The SIV p27 Gag CE antigen 
in combination with an HIV-1 Env CE DNA vaccine in 
macaques resulted in potent CE-specific CD8+ T-cell 
responses and did not show control of viremia but a 
reverse correlation of p27 Gag CE-specific CD8+ T-cells 
and peak viremia [10].
We approached the objective of focusing the T-cell 
response on conserved parts of Gag from a different 
angle in Andersson and Holst [11]. We vaccinated out-
bred mice with virus-like vaccines (VLVs), i.e. virus-
vectored virus-like particle (VLP) vaccines, encoding 
Gag and Env. Human adenovirus type 5 (Ad) served as 
a prime and modified vaccinia virus Ankara (MVA) as 
a boost vector. The origin of Gag was varied between 
HIV-1 consensus clade B (HIVconB) in the prime and 
SIVmac239 in the boost to selectively expand CD8+ 
T-cell responses to epitopes shared between the heter-
ologous Gags. For comparison, a second group received 
homologous SIVmac239 Gag in both prime and boost 
immunization. All VLVs  encoded SIVmac239 Env 
downstream of Gag to induce Env-specific antibody 
responses which have been shown to benefit from 
Env-presentation on VLPs [12–14]. In mice vaccinated 
with homologous Gag higher and broader Gag-specific 
CD8+ T-cell responses and more Env-specific antibod-
ies were detected compared to mice receiving heterol-
ogous Gag. Furthermore, the mice in the homologous 
Gag group raised more Gag- than Env-specific CD8+ 
T-cells. The opposite was true for differing Gags, which 
suggests immunodominance of the homologous Env 
over the heterologous Gag [11].
The first antigens targeted by CD8+ T-cells in a natural 
HIV-1 infection are often Env and Nef followed by p24 
Gag and DNA polymerase (Pol). To completely avoid 
these immunodominant antigens during vaccination, we 
chose the approach described in Xu et al. [15]: only the 
SIVmac239 subdominant accessory antigens trans-acti-
vator of transcription (Tat), viral infectivity factor (Vif ), 
regulator of expression of virion proteins (Rev) and viral 
protein R (Vpr) were encoded in adenovirus-vectored 
vaccines. To increase the intrinsically low immuno-
genicity of these antigens, we included the genetic T-cell 
adjuvant MHC class II-associated invariant chain (Ii). 
An invariant chain vaccine has been shown to induce 
a degree of acute protection in a rodent LCMV model 
which enabled the infection to broaden the response to 
dominant antigens [16]. In combination with the SIV-
mac239 subdominant accessory antigens, the vaccina-
tion regimen induced accessory antigen-specific CD8+ 
T-cells in a prime and boost immunization of non-human 
primates (NHPs) which were subsequently challenged 
by SIV. The vaccinated NHPs showed profound control 
of acute infection (2/6 completely controlling infection 
following 10 challenges) and all vaccinated animals had 
long-term immunological benefits such as reduced rectal 
CD4+ T-cell depletion and highly limited CD8+ T-cell 
hyperactivation [15].
Also in Martins et al. rhesus macaques vaccinated with 
the accessory antigens Vif, Rev, Tat and negative factor 
(Nef) became detectably infected at a slower rate than 
controls and animals that received accessory antigens 
in combination with Gag and/or Env [17]. Interestingly, 
immunization with all these antigens led to the best con-
trol of chronic viremia after SIV acquisition. In Hel et al. 
Rev, Tat and Nef were added to a vaccine consisting of 
Gag, Pol and Env. This resulted in a delay and reduction 
of SIV viremia in NHPs, a better preservation of virus-
specific CD4+ T-cells and increased survival [18]. These 
findings suggest that combining the immunodominant 
antigens Gag and Env with subdominant, accessory anti-
gens could result in better protection and viral control, 
with the caveat that Env-specific T-cell responses are not 
protection-associated and are immunodominant.
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In this study we aimed to overcome the Env immuno-
dominance over Gag observed in Andersson and Holst 
by using both heterologous Gag and Env in a VLV Ad-
prime  MVA-boost regimen in outbred mice. A positive 
side effect of additionally varying Env between prime 
and boost could be the induction of broader antibody 
responses for protection against infection. We also 
hypothesized that including CEs could help to focus the 
T-cell response on more protective Gag epitopes, ulti-
mately leading to better long-term control of viremia. 
In addition, we assessed if a combination of the immu-
nodominant Gag and Env antigens with subdominant 
accessory antigens could result in responses associated 
with protection as suggested by Xu et al., Martins et al. 
and Hel et al. [15, 17, 18]. To this end, we combined the 
homologous Gag/Env immunization from Andersson 
and Holst and the heterologous Gag/Env vaccination 
with an additional Ad prime encoding Ii, SIV p27 Gag 
CEs and SIVmac239 Rev, Vif and Vpr (Ad-Ii-SIVCErvv).
In the heterologous Gag/Env prime-boost regimen Env 
dominance could be successfully avoided. When includ-
ing Ad-Ii-SIVCErvv Env dominance reappeared, but nev-
ertheless more cross-reactive Gag-specific CD8+ T-cell 
and antibody responses to Env were elicited. Adding Ad-
Ii-SIVCErvv to the homologous Gag/Env prime-boost 
not only induced accessory antigen-specific CD8+ T-cell 
memory responses, but also significantly increased the 
ratio of Gag- to Env-specific CD8+ T-cells. The CD4+ 
T-cell response further shifted away from the structural 
antigens previously associated with infection-enhance-
ment [19]. We can conclude that adding Ad-Ii-SIVCErvv 
to the homologous Gag/Env prime-boost regimens acted 
synergistically to induce diverse responses, each which 
have previously been associated with partial protection 
independently.
Methods
Mice
Female CD1 mice were obtained from Envigo (United 
Kingdom) at the age of 6–8 weeks and allowed to accli-
matize for 1  week before an experiment was initiated. 
All experiments were performed according to national 
guidelines and experimental protocols approved by the 
national animal experiments inspectorate (Dyreforsøg-
stilsynet, permit ID: 2016-15-0201-01131).
Viral vector production
The expression cassettes for adenovirus production con-
sisted of the genes of interest under the control of a CMV 
promoter, a Tet operator and a simian virus 40 polyade-
nylation signal. For the 2 adenoviral virus-like vaccines, 
HIV-1 consensus clade B Gag and HIV-1 JR-FL Env 
(resulting virus: Ad-HIVB) or SIVmac239 Gag and Env 
(resulting virus: Ad-SIV, used in Andersson and Holst 
[11]) were linked by a glycine-serine-glycine linker and 
a self-cleavable porcine teschovirus-1 2A (P2A) peptide. 
For the additional adenoviral vector, the C-terminus of 
the mouse Ii (aa 1–75) was fused to SIV p27 CEs and 
Rev, Vif and Vpr from SIVmac239 (resulting virus: Ad-
Ii-SIVCErvv). These were encoded in the expression cas-
sette, which was inserted into the E1 region of an E1/
E3-deleted replication-deficient human adenovirus type 
5 backbone by homologous recombination in BJ5183 E. 
coli cells. The Ad vectors were produced in ProVector™ 
cells (Sirion Biotech GmbH, Germany) and purified using 
a CsCl gradient as described [20]. For titration ProVec-
tor™ cells were infected for 46 h, fixed and virus plaques 
stained using an anti-adenovirus hexon protein antibody 
(Santa Cruz Biotechnology) followed by a horseradish 
peroxidase (HRP)-conjugated goat anti-mouse immu-
noglobulin antibody (Dako) and 3,3′-diaminobenzidine 
substrate. The infectious units (IFU) per mL were deter-
mined by counting stained virus plaques.
The MVA-SIV vector encoding SIVmac239 Gag, Pol 
and Env (truncated at aa  733) was kindly provided by 
Dr. Patricia L. Earl (National Institutes of Health (NIH), 
USA). The production and titration of MVA vectors was 
carried out as described elsewhere [21].
In vitro characterization of Ad‑HIVB
VLP purification and Western Blot
Vero cells were seeded and infected with 50 IFU/cell Ad-
HIVB. 48 h post infection the supernatant was harvested 
and VLPs were purified and concentrated to 160× the 
original concentration as described [22].
The Gag-P2A protein was detected in VLP samples by 
Western Blot using an anti-2A peptide antibody (Milli-
pore) followed by an HRP-conjugated goat anti-rabbit Ig 
antibody. The membrane was developed using LumiGLO 
Peroxidase Chemiluminescent Substrate (KPL, 54-61-00) 
and the signal detected in an ImageQuant LAS 4000 (GE 
Healthcare Life Sciences).
Cell surface expression analysis
Env surface expression on Vero cells was analyzed 2 days 
post infection with 50 IFU/cell Ad-HIVB. The cells were 
stained with the monoclonal antibody clones VRC01 
[NIH AIDS Reagent Program (NARP)], PGT145 [Inter-
national AIDS Vaccine Initiative (IAVI)] and PGT151 
(IAVI). Binding of the antibodies was detected using 
anti-human IgG Fc-APC antibody (BioLegend, 409305) 
and the fluorescence of the cells acquired in an LSRII 
instrument (BD Biosciences). The data was analyzed with 
FlowJo 10 software (Tree Star, Ashland, OR).
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Immunizations
Table  1 shows which viruses, IFUs and injection sites 
were used for the immunizations in the different experi-
ments. Vaccines were injected intramuscularly in a total 
volume of 50 µL PBS under isoflurane anaesthesia.
Intracellular cytokine staining (ICS)
Mouse splenocytes were stimulated at 37 °C and 5%  CO2 
for 5 h with relevant peptide pools at 1 ng/µL (test of Ad-
Ii-SIVCErvv, homologous prime-boost) or 0.67  ng/µL 
(test of Ad-HIVB, heterologous prime-boost) and 3  µM 
Monensin. Peptides were obtained from the NARP and 
the SIV CE peptide pool was constructed as described 
[11]. Subsequently, cells were stained according to 
standard protocols [23, 24] using anti-mouse antibod-
ies (Biolegend): PerCP/Cy5.5-CD8, FITC-CD4, Pacific 
Blue™-B220, APC/Cy7-CD44, APC-IFNγ, PE/Cy7-TNFα. 
Flow cytometry was performed in an LSRII instrument 
(BD Biosciences) and the data analyzed with FlowJo 10 
software (Tree Star, Ashland, OR) using the gating strat-
egy shown in Additional file 1.
Antibody response measurements
Antibody responses against the Env protein from SIV-
mac239, HIV-1 clade B and HIV-1 clade C were meas-
ured by enzyme linked immunosorbent assay (ELISA) 
as described [11]. Env was produced from the HIV-1 
clade B clone BaL.26 (NARP), clade C clone Du172.17 
SVPC4 (NARP) and SIVmac239 (cloned by Anne-Marie 
C. Andersson). Antibody titers in the homologous prime-
boost experiment were calculated as the highest dilution 
factor of the serum with an absorbance exceeding the 
mean absorbance using serum from unvaccinated con-
trol animals + 3 standard deviations. The area under the 
curve was calculated from the absorbance curve using 
GraphPad Prism 7 software. For the avidity index the 
titer obtained with sodium citrate treatment was divided 
by the titer obtained without sodium citrate treatment. 
For analyzing the isotype of the induced antibodies, the 
serum dilution, which resulted in an absorbance of 2.0 in 
the previous ELISA, was used and isotype specific bind-
ing was measured in duplicates. HRP-linked goat anti-
mouse secondary antibodies for IgG2a, IgG2b, IgG2c and 
IgG3 (Thermo Fisher Scientific) were used.
Table 1 Summary of  all immunization regimens showing the  times  of immunization (with viruses, IFUs and  injections 
sites used), bleeding to  obtain serum samples to  assess antibody responses and  intracellular cytokine staining (ICS) 
for the analysis of T-cell responses
Experiment Group Time Intervention Virus IFU/mouse Injection site
Immunogenicity of Ad‑HIVB – Day 0 Immunization Ad‑HIVB 1 × 108 Lower right leg
Day 18 ICS
Immunogenicity of Ad‑Ii‑SIVCErvv – Day 0 Immunization Ad‑Ii‑SIVCErvv 2 × 108 Lower right leg
Day 14 ICS
Heterologous HIV‑prime SIV‑boost without Ad‑Ii‑SIVCErvv Day 0 Prime immunization Ad‑HIVB 1 × 108 Lower right leg
Day 50–57 Bleeding
Day 63–74 Boost immunization MVA‑SIV 5 × 107 Lower right leg
10 days post boost Bleeding & ICS
with Ad‑Ii‑SIVCErvv Day 0 Prime immunization Ad‑HIVB 1 × 108 Lower right leg
Ad‑Ii‑SIVCErvv 1 × 108 Lower left leg
Day 50–57 Bleeding
Day 63–74 Boost immunization MVA‑SIV 5 × 107 Lower right leg
10 days post boost Bleeding & ICS
Homologous SIV‑prime SIV‑boost without Ad‑Ii‑SIVCErvv Day 0 Prime immunization Ad‑SIV 2 × 108 Upper right leg
Day 56 Bleeding &
Boost immunization MVA‑SIV 1 × 107 Upper left leg
Day 311 Bleeding & ICS
with Ad‑Ii‑SIVCErvv Day 0 Prime immunization Ad‑SIV 2 × 108 Upper right leg
Ad‑Ii‑SIVCErvv 2 × 108 Upper left leg
Day 56 Bleeding &
Boost immunization MVA‑SIV 1 × 107 Upper left leg
Day 311 Bleeding & ICS
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Statistical analysis
Two-tailed, unpaired Mann–Whitney U tests were 
performed to compare immune responses between 
2  groups or responses to 2 different peptide pools in 
one group. Significances are indicated by asterisks: * 
p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. To assess correlations 
Spearman correlation was used followed by adjustment 
of p-values by the Holm–Sidak method. Statistical anal-
yses were performed using GraphPad Prism 7 software.
Results
Vaccine design and characterization
Design of VLVs
We aimed to overcome the Env dominance in the het-
erologous Gag/homologous Env prime boost regimen 
in Andersson and Holst [11] by using both heterolo-
gous Gag and Env in prime and boost. Therefore, we 
designed a new Ad VLV encoding HIVconB Gag and 
HIV-1 JR-FL (clade B) Env (Ad-HIVB; Fig. 1a) to com-
bine it with the MVA boost encoding SIVmac239 Gag, 
Pol and Env (MVA-SIV) in mice [11]. For the homolo-
gous Gag/Env prime-boost regimen we used the Ad-
SIV (encoding SIVmac239 Gag and Env) and MVA-SIV 
VLVs from Andersson and Holst [11] (Fig.  1a). As the 
functionality of Ad-SIV had already been shown in the 
previous study, here we characterized only the Ad-
HIVB VLV in vitro and in vivo.
Ad‑HIVB expresses the encoded antigens and is immunogenic 
in mice
Ad-HIVB-infected Vero cells were stained for HIV-1 
Env with three different broadly neutralizing mono-
clonal antibodies (VRC01, PGT145, PGT151). Analysis 
by flow cytometry confirmed cell surface expression of 
Env (Fig. 1b). We further assessed VLP formation capa-
bility of the VLV by Western Blot analysis of VLPs puri-
fied from the media of Ad-HIVB-infected Vero cells. In 
two independent experiments Gag-P2A was detectable 
with the expected band size of approx. 58 kDa (Fig. 1c).
To analyze the immunogenicity of the construct we 
vaccinated 5 CD1 mice with Ad-HIVB and measured 
the vaccine-induced T-cell responses after 18  days by 
ICS followed by flow  cytometry (Fig.  1d). Ad-HIVB 
induced high numbers of HIVconB Gag-specific CD8+ 
T-cells, which were significantly higher than the HIV-
conB Env-specific CD8+ T-cell responses. CD4+ T-cell 
responses to HIVconB Gag were comparably high, tak-
ing into account that less CD4+ than CD8+ T-cells are 
found in the spleen. The number of Env-specific CD4+ 
T-cells was slightly lower than for Gag. These results 
confirm antigen-expression and VLP-formation by Ad-
HIVB in cells and its immunogenicity in mice.
Ad‑Ii‑SIVCErvv induces T‑cell responses to the accessory 
antigens
We aimed to further improve on the heterologous and 
homologous prime-boost regimen by inducing CD8+ 
T-cell responses to accessory antigens for acute control 
of infection and cross-reactive CE-specific CD8+ T-cell 
responses. To this end, we constructed a separate adeno-
viral vector encoding a fragment of the mouse Ii  T-cell 
adjuvant, SIV CEs and SIVmac239 subdominant acces-
sory proteins Rev, Vif and Vpr (Ad-Ii-SIVCErvv) as one 
fusion protein (Fig.  1a). 10 CD1 mice were vaccinated 
with Ad-Ii-SIVCErvv and the T-cell responses analyzed 
by ICS after 14  days (Fig.  1e). Few, low CD8+ T-cell 
responses could be measured to SIV CE and SIVmac239 
Rev, but all animals showed high numbers of Vif- and 
Vpr-specific CD8+ T-cells. CD4+ T-cell responses to 
Rev were only found in a few mice in high numbers while 
Vif-specific CD4+ T-cell responses were induced in most 
animals. This shows that Ad-Ii-SIVCErvv raises T-cell 
responses to the encoded antigens in outbred mice.
Heterologous HIV‑prime SIV‑boost regimen
For an experiment with heterologous Gag and Env in 
prime and boost we vaccinated 4 groups of mice. Two 
groups received only the priming vectors Ad-HIVB or 
Ad-HIVB together with Ad-Ii-SIVCErvv, the other two 
groups an additional MVA-SIV boost approx. 9–10 weeks 
after the prime. 10  days later we took serum samples 
to assess antibody responses and performed an ICS on 
splenocytes to analyze T-cell responses. In this time 
frame after MVA boosting the highest T-cell responses 
were expected as well as prominent antibody responses 
[25, 26]. In addition to peptide pools corresponding to 
the vaccine antigens (except Rev, Vif and Vpr), we used 
a peptide pool for SIVagm  vervet (SIVagm) Gag to test 
the breadth and cross-reactivity of the induced Gag-spe-
cific T-cell responses. The sequence difference/similar-
ity is roughly the same between HIVconB, SIVmac239 
and SIVagm Gag [11].
CD8+ T‑cell responses induced by heterologous HIV‑prime 
SIV‑boost regimen
In the two groups receiving only the priming vector Ad-
HIVB with or without Ad-Ii-SIVCErvv, no significant 
differences were detectable in CD8+ T-cell responses 
towards Gag or Env epitopes (Fig. 2a). The CD8+ T-cell 
response to HIVconB Gag was significantly stronger than 
to HIVconB Env in both groups and the Ad-Ii-SIVCErvv 
group showed slightly broader responses to the differ-
ent Gags and SIV CE. Including the MVA-SIV boost, 
Page 6 of 18Schwerdtfeger et al. J Transl Med          (2019) 17:175 
HIVconB Gag-specific CD8+ T-cell responses were sig-
nificantly higher in the group without Ad-Ii-SIVCErvv, 
while the SIV CE- and SIVagm Gag-specific responses 
were significantly higher in the Ad-Ii-SIVCErvv group 
(Fig.  2b). In the boosted Ad-Ii-SIVCErvv group we 
observed significantly more HIVconB Env-specific CD8+ 
T-cells than without the boost (p = 0.0468), which was 
not observed for the group without Ad-Ii-SIVCErvv. As 
SIVmac239 Gag SIVmac239 Env
HIVconB Gag HIV JR-FL (clade B) Env
P2A
P2A
Ad-HIVB
Ad-SIV
SIVmac239
Rev VprSIV CEIi VifAd-Ii-SIVCErvv
a
VRC01 PGT145 PGT151
b
71
48
33
96
kDa
c
d e
APC-A: HIV EnvAPC-A: HIV EnvAPC-A: HIV Env
Fig. 1 Design of adenoviral vectors and characterization in vitro and in vivo. a Schematic representation of the adenoviral vectors used in the 
study: Ad‑HIVB encodes HIV‑1 consensus clade B (HIVconB) Gag, P2A preceded by a glycine‑serine‑glycine linker (GSG; not noted in the figure) and 
HIV‑1 JR‑FL (clade B) Env; Ad‑SIV encodes SIVmac239 Gag and Env separated by GSG and P2A; Ad‑Ii‑SIVCErvv encodes mouse Ii aa 1–75 (Ii) fused 
to SIV CEs and SIVmac239 Rev, Vif and Vpr. b Vero cells were infected with 50 IFU/cell Ad‑HIVB and were stained after 2 days with the monoclonal 
antibodies VRC01, PGT145 and PGT151 targeting HIV‑1 Env (shown in dark grey). APC‑labelled anti‑human IgG Fc served as a secondary antibody 
and the cells were analyzed by flow cytometry. Uninfected stained cells served as a control (light grey). c Vero cells were infected with 50 IFU/cell 
Ad‑HIVB and after 48 h VLPs were purified from the cell culture supernatant. The VLP samples were analyzed by SDS‑PAGE followed by Western 
Blot, which was stained with an anti‑P2A antibody. Cells infected with an Ad5 vector not encoding P2A (Ad‑noP2A) served as a negative control. d 
CD1 mice were vaccinated with Ad‑HIVB (n = 5) and the induced T‑cell responses were analyzed 18 days later by intracellular cytokine staining of 
stimulated splenocytes. The peptide pools used for stimulation are noted on the X‑axis. The total numbers of IFNγ+ CD8+ and CD4+ T‑cells per 
spleen were measured by flow cytometry. Horizontal lines indicate the geometric mean and significant differences are marked by asterisks with 
*(p ≤ 0.05). e CD1 mice were immunized with Ad‑Ii‑SIVCErvv (n = 10). After 14 days CD8+ and CD4+ T‑cell responses to the vaccine antigens were 
analyzed as in d 
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a result, in the group without Ad-Ii-SIVCErvv, CD8+ 
T-cell responses to HIVconB  Gag were significantly 
higher than to HIVconB Env. Accordingly, the completely 
heterologous prime-boost regimen could overcome the 
immunodominance of Env that has been observed when 
only varying Gag [11], but it could not select for cross-
reactive or CE-specific CD8+ T-cell responses. In combi-
nation with Ad-Ii-SIVCErvv the CD8+ T-cell responses 
to HIVconB Gag were even slightly lower than to HIV-
conB Env, indicating a reappearance of Env dominance. 
However, addition of Ad-Ii-SIVCErvv to the vaccination 
regimen increased the breadth of CD8+ T-cell responses 
to the different Gags tested, which could potentially be 
explained by the included CEs priming T-cell specificities 
with broadened recognition of Gag sequences.
CD4+ T‑cell responses induced by the heterologous 
HIV‑prime SIV‑boost regimen
Without the boost, the highest CD4+ T-cell responses 
were induced to HIVconB Gag. In the group without Ad-
Ii-SIVCErvv these responses were significantly higher 
than HIVconB Env-specific CD4+ T-cell responses 
(Fig. 2c).
a bPrime Prime + Boost
c dPrime Prime + Boost
C
D
8+
C
D
4+
Fig. 2 CD8+ and CD4+ T‑cell responses elicited by heterologous HIV‑prime SIV‑boost regimen. We vaccinated CD1 mice with a, c only the priming 
vectors Ad‑HIVB or Ad‑HIVB together Ad‑Ii‑SIVCErvv or b, d boosted them with MVA‑SIV approx. 9–10 weeks after the prime (n = 10 for each group). 
10 days after the boost we measured the numbers of IFNγ+ CD8+ (a, b) and CD4+ (c, d) T‑cells per spleen by stimulating splenocytes with the 
noted peptide pools and analyzing them by intracellular cytokine staining followed by flow cytometry. Horizontal lines mark the geometric mean 
and significant differences are indicated by asterisks with *(p ≤ 0.05), **(p ≤ 0.01) and ***(p ≤ 0.001)
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Boosting vaccination with MVA-SIV had only a moder-
ate effect on most specificities but significantly increased 
the CD4+ T-cell responses to SIV CE in the Ad-Ii-
SIVCErvv group (p = 0.0251) and SIVmac239 Env in both 
groups (p < 0.001) (Fig. 2d). This resulted in CD4+ T-cell 
responses dominated by SIVmac239 Env in both groups 
and slightly broader responses to the Gags/CE in the Ad-
Ii-SIVCErvv group.
Heterologous HIV‑prime SIV‑boost regimen induced broad 
Env‑specific antibody responses
Vaccine-induced antibody responses to the 2 Env protein 
trimers used for immunizations (SIVmac239 and HIV-1 
clade B Env) and additionally to HIV-1 clade C, to test 
cross-clade-reactivity, were tested by ELISA (Fig. 3). In all 
4 vaccination groups cross-reactive antibody responses 
to Env were elicited, indicating broad lentivirus-specific 
responses induced by the VLVs. Boosting with MVA-SIV 
had little effect, but in combination with Ad-Ii-SIVCErvv 
in the prime yielded responses against all 3 tested Envs 
that were significantly higher than in the boosted group 
without Ad-Ii-SIVCErvv.
Correlations of immune responses induced by heterologous 
HIV‑prime SIV‑boost regimen
The T-cell and antibody responses measured in the 
boosted groups were analyzed for correlations using 
Spearman correlation and the obtained p-values were 
adjusted for multiple comparisons using the Holm–Sidak 
method.
Without Ad-Ii-SIVCErvv the SIVmac239 Gag- and 
HIVconB Env-specific CD8+ T-cell responses as well 
as antibody responses to SIVmac Env and HIV-1 clade 
C Env correlated significantly (Table  2a). In the Ad-Ii-
SIVCErvv-vaccinated group CD4+ T-cell responses to 
each of the following peptide pools were significantly cor-
related with the CD8+ T-cell response to the same pool: 
HIVconB Gag, SIVmac239 Gag, SIV CE, SIVagm Gag, 
HIVconB Env and SIVmac239 Env (Table  2b). Besides, 
CD4+ and CD8+ T-cell responses to SIVmac239 Gag 
correlated significantly with CD4+ and CD8+ T-cell 
responses to SIVagm Gag. Antibody responses to HIV-1 
clade B Env and HIV-1 clade C Env were correlated.
Homologous SIV‑prime SIV‑boost regimen
In addition to optimizing the prime-boost regimen from 
Andersson and Holst by using heterologous Env, we also 
tested if we could improve on the prime-boost regimen 
from Andersson and Holst with homologous SIVmac239 
Gag and Env by adding Ad-Ii-SIVCErvv [11]. Therefore, 
we vaccinated 2 groups of mice with the Ad-SIV prime 
with one group receiving the additional priming vector 
Ad-Ii-SIVCErvv. The mice were boosted with MVA-SIV 
8  weeks after the prime and the T-cell and antibody 
responses were analyzed 8  months after the boost. 
Andersson  and Holst had already analyzed the acute 
responses following homologous prime-boost immuni-
zation and our results in the heterologous prime-boost 
indicated that the Ad-Ii-SIVCErvv vaccine could alter 
antibody responses. Therefore, we chose a late time point 
after vaccination to assess the effect of Ad-Ii-SIVCErvv 
on the memory T-cell and antibody responses induced 
by the vaccines. All peptide pools used in this study were 
from SIVmac239.
a
c
b Anti-SIVmac239 Env
Anti-HIV C Env
Anti-HIV B Env
Fig. 3 Heterologous HIV‑prime SIV‑boost regimen induced broadly 
reactive Env‑specific antibody responses. Serum samples were 
taken 10 days after the boost and analyzed for antibody binding to 
lyzed pseudoviruses carrying a HIV‑1 clade B (HIV B), b SIVmac239 
and c HIV‑1 clade C (HIV C) Env, by ELISA. Horizontal lines indicate the 
geometric mean and significant differences are marked by asterisks 
with *(p ≤ 0.05), **(p ≤ 0.01) and ***(p ≤ 0.001)
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CD8+ T‑cell responses induced by homologous SIV‑prime 
SIV‑boost regimen
High Gag- and Env-specific CD8+ T-cell responses 
were present in both groups, but responses to Gag were 
higher when Ad-Ii-SIVCErvv  was administered addi-
tionally (Fig.  4a). Env-specific CD8+ T-cell responses 
in the group without Ad-Ii-SIVCErvv were significantly 
stronger than Gag-specific responses in the same group 
and Env-specific responses in the Ad-Ii-SIVCErvv-
vaccinated group. As a result, the ratio of Gag- to 
Env-specific CD8+ T-cells was significantly higher in 
the Ad-Ii-SIVCErvv group (p = 0.0021). In the Ad-Ii-
SIVCErvv group some low CD8+ T-cell responses were 
detectable to Rev and moderate and comparably high 
responses to Vif and Vpr, with the latter 2 being signifi-
cantly higher than the responses to these antigens in the 
group without Ad-Ii-SIVCErvv.
To evaluate the functionality of the vaccine-induced 
memory CD8+ T-cells we analyzed which percentage 
of IFNγ+ CD8+ T-cells simultaneously produced TNFα 
(Fig. 4b). Only samples with more than  104 IFNγ+ CD8+ 
T-cells per spleen were considered, which was the case 
for all Gag- and Env-specific CD8+ T-cell responses and 
for the majority of Vif- and Vpr-specific CD8+ T-cell 
responses. Nearly all mice showed more than 50% dou-
ble-positive cells for the tested vaccine antigens with geo-
metric means between 65% and 85%, indicating that the 
quality of induced CD8+ T-cells was good and did not 
differ distinctly between groups.
CD4+ T‑cell responses induced by homologous SIV‑prime 
SIV‑boost regimen
When mice were vaccinated with the homologous prime-
boost without Ad-Ii-SIVCErvv, higher numbers of CD4+ 
T-cells reacted to Gag and significantly more CD4+ 
T-cells reacted to Env than in mice vaccinated with the 
additional prime (Fig.  4c). In the group without Ad-Ii-
SIVCErvv, background CD4+ T-cell responses to the 
accessory antigens were observed and addition of Ad-
Ii-SIVCErvv had only a remote effect on CD4+ T-cell 
responses towards Rev and Vif. Furthermore, responses 
to Vpr were not affected by including Ad-Ii-SIVCErvv 
indicating variation around the background response lev-
els in the assay.
The percentage of IFNγ TNFα double-positive cells 
for Env-specific CD4+ T-cells was consistently positive, 
with a geometric mean above 60% for both groups and no 
detectable difference (Fig. 4d).
Antibody responses induced by homologous SIV‑prime 
SIV‑boost regimen
In order to assess antibody responses, we calculated the 
titer as well as the area under the curve (AUC), which 
both did not differ significantly between the groups 
(Fig. 5a, b). In addition, the avidity of antibodies did not 
differ between the groups (Fig. 5c).
The induction of different IgG isotypes was further 
analyzed and is depicted in Fig.  5d as the AUC ratio to 
whole IgG serum antibodies detected using an isotype-
unspecific pan-IgG secondary antibody. The ratio of 
IgG2a antibodies to total IgG or IgG1 has been proposed 
as a functional association with protective antibodies in 
some models in inbred mice, however, it was quite evi-
dent that CD1 mice were heterogenous for IgG2a and 
IgG2c, which made it impossible to produce meaningful 
ratios including either isotype. Nevertheless, more IgG2a 
and IgG2c than IgG2b were induced with no signifi-
cant differences between the groups while no IgG3 was 
detected.
Correlation of immune responses induced by homologous 
SIV‑prime SIV‑boost regimen
In the group without Ad-Ii-SIVCErvv the AUC and titer 
of antibody responses correlated significantly (Table 3a). 
In the group with Ad-Ii-SIVCErvv, Env- and Vpr-specific 
CD4+ T-cell responses showed significant correlation 
(Table  3b). In addition, both the AUC and titer of the 
antibody responses correlated significantly with the avid-
ity index.
Discussion
To induce protective B-cell responses and avoid the dom-
inance of non-protective Env-specific T-cell responses 
observed in Andersson and Holst [11], we tested an 
immunization regimen using both heterologous Gag and 
Env in prime and boost. Therefore, we constructed a VLV 
(Ad-HIVB) encoding HIVconB Gag and HIV-1 JR-FL 
Env (clade B). We confirmed antigen expression and VLP 
formation in vitro and the immunogenicity of the vector 
in vivo (Fig. 1a–d).
As a second goal we aimed to focus the CD8+ T-cell 
response on putatively more protective Gag CEs and to 
induce T-cell responses to accessory antigens which have 
been shown to improve early control of infection [15, 
17, 18]. An adenovirus encoding a fragment of the Ii, 
SIV CEs, SIVmac239 Rev, Vif and Vpr (Ad-Ii-SIVCErvv; 
Fig. 1a) was used as an additional prime in the heterol-
ogous as well as homologous vaccination regimen from 
Andersson and Holst. Immunization of outbred CD1 
mice with this vector alone induced few CD8+ T-cell 
responses to SIV CE, strong CD8+ T-cell responses to Vif 
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and Vpr and some animals raised high numbers CD4+ 
T-cells to Rev and most to Vif (Fig. 1e). We hypothesized 
that, even though priming of SIV CE-specific T-cell 
responses was not very strong with this vector, they could 
be boosted by full-length Gag encoded in MVA-SIV and 
that even minor T-cell responses towards the CEs might 
influence response to Gag-containing VLPs.
Heterologous HIV‑prime SIV‑boost experiment
In the heterologous prime-boost regimen the primes 
alone (Ad-HIVB or Ad-HIVB together with Ad-
Ii-SIVCErvv) induced more HIVconB Gag- than 
Env-specific CD8+ T-cell responses (Fig. 2a). The MVA-
SIV boosted group without Ad-Ii-SIVCErvv showed 
significantly higher numbers of HIVconB Gag- than 
HIVconB Env-specific CD8+ T-cells (Fig.  2b). This 
observation indicates that the completely heterologous 
prime-boost regimen successfully prevented the Env 
immunodominance of the partly heterologous regi-
men (heterologous Gag + homologous Env) observed in 
Andersson and Holst [11]. Considering solely the T-cell 
response, a  better viral control should be achieved as 
lower viral loads have been shown to correlate directly 
a b
c d
C
D
8+
C
D
4+
Fig. 4 CD8+ and CD4+ T‑cell responses induced by homologous SIV‑prime SIV‑boost regimen. CD1 mice were immunized with the priming 
vectors Ad‑SIV (n = 9) or Ad‑SIV and Ad‑Ii‑SIVCErvv (n = 10) and boosted with MVA‑SIV 8 weeks after the prime. 10 days later CD8+ and CD4+ 
T‑cell responses were measured by stimulating splenocytes with the noted SIVmac239 peptide pools and analyzing them by intracellular cytokine 
staining followed by flow cytometry. a, c show the total numbers of IFNγ+ CD8+ (a) and CD4+ (b) T‑cells per spleen and b, d the percentage of 
IFNγ+ TNFα+ CD8+/CD4+ T‑cells of IFNγ+ CD8+/CD4+ T‑cells for samples with more than  104 IFNγ+ CD8+ T‑cells. Horizontal lines mark the 
geometric mean and significant differences are indicated by asterisks with *(p ≤ 0.05), **(p ≤ 0.01) and ***(p ≤ 0.001)
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with CD8+ T-cell responses targeting Gag and inversely 
with CD8+ T-cells specific for Env in humans [4, 5].
Unfortunately, the heterologous Gag/Env immuniza-
tion regimen failed to raise the expected broadly reactive 
Gag-specific CD8+ T-cell responses since responses to 
SIV CE and SIVagm Gag were still low.
Notably, the heterologous immunization regimen 
in combination with Ad-Ii-SIVCErvv succeeded in 
raising broader Gag/CE-specific CD8+ and CD4+ 
T-cell responses than the immunization without Ad-
Ii-SIVCErvv (Fig.  2b). These broad responses could 
be explained by the priming of SIV CE-specific T-cell 
responses by Ad-Ii-SIVCErvv, which were detectable 
in mice receiving only the prime, although they were 
not significantly higher than in the group without Ad-
Ii-SIVCErvv. In the boosted Ad-Ii-SIVCErvv group SIV 
CE-specific responses were indeed slightly higher than 
in the group with only the prime which is in accordance 
with the results from Kulkarni et al. who found that CE-
specific T-cell responses could be boosted by vaccination 
with full-length Gag [8].
In the Ad-Ii-SIVCErvv group CD4+ T-cell responses 
to one peptide pool correlated significantly with the 
CD8+ T-cell responses to the same pool (Table  2b), 
which was true for all peptide pools in this group. In 
contrast there was no correlation between CD4+ and 
CD8+ T-cell responses to the same antigen in the 
group without Ad-Ii-SIVCErvv (Table  2a). This sug-
gests that the inclusion of Ad-Ii-SIVCErvv in the 
immunization regimen through an unknown mecha-
nism influenced the CD4+ and CD8+ T-cell responses 
to the same antigen. These correlations led us to 
Fig. 5 Addition of Ad‑Ii‑SIVCErvv to homologous SIV‑prime SIV‑boost regimen did not impact Env‑specific antibody responses. Serum samples 
were taken at the time of the intracellular cytokine staining and analyzed for antibody binding to lyzed pseudoviruses carrying SIVmac239 Env by 
ELISA. a shows the antibody responses as titers and b as the AUC. In c the avidity index is depicted and in d the antibody responses detected with 
anti‑IgG isotype‑specific antibodies as the ratio to the not isotype‑specific antibody (pan‑IgG). Horizontal lines indicate the geometric mean, except 
in c where it depicts the mean because of a single mouse not having a measurable avidity index
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hypothesize that CD4+ T-cells might preferentially 
stimulate CD8+ T-cells with specificity to the same 
antigen in the boosted Ad-Ii-SIVCErvv group. Broader 
Gag/CE-specific CD4+ T-cell responses with higher 
magnitude were elicited compared to the group with-
out Ad-Ii-SIVCErvv (Fig.  2d), although the differences 
were not statistically significant. If these would prefer-
entially provide T-cell help to CD8+ T-cells with the 
same specificity, they could help boost the observed 
cross-reactive Gag/CE-specific CD8+ T-cell responses. 
The assumption that these CD8+ T-cell responses are 
indeed cross-reactive and do not merely result from 
different specificities, is supported by the strong cor-
relation between SIVmac239 Gag-specific CD4+ and 
CD8+ T-cell responses and SIVagm Gag-specific CD4+ 
and CD8+ T-cell responses (Table 2b). Regarding solely 
Table 3 Correlation of T-cell and antibody responses in the homologous SIV-prime SIV-boost regimen
p-values of Spearman correlation in MVA-SIV-boosted groups a without Ad-Ii-SIVCErvv and b with Ad-Ii-SIVCErvv. p-values that remained significant after adjustment 
with the Holm–Sidak-method are marked in italic
a
Ad‑SIV
+ MVA‑SIV
CD4+ T‑cells CD8+ T‑cells Antibodies
Gag Env Rev Vif Vpr Gag Env Rev Vif Vpr AUC Titer Avidity
CD4+ T‑cells
Gag
Env 0.086
Rev 0.085 0.834
Vif 0.694 0.250 0.792
Vpr 0.262 0.731 0.342 0.444
CD8+ T‑cells
Gag 0.678 1.018 0.151 0.500 0.363
Env 0.437 0.410 0.611 0.889 0.082 0.017
Rev 0.516 0.131 0.960 0.583 0.187 0.226 0.226
Vif 0.476 0.901 0.181 1.000 0.782 0.615 0.460 0.940
Vpr 0.667 1.111 0.889 0.222 0.889 0.667 0.444 1.000 0.333
Antibodies
AUC 0.097 0.776 0.228 0.944 0.853 0.644 0.948 0.583 0.226 0.444
Titer 0.263 0.630 0.337 0.889 0.673 0.616 0.913 0.230 0.480 0.667 0.001
Avidity 0.083 1.000 0.139 1.583 0.056 0.583 0.778 1.417 1.417 1.778 1.000 0.750
b
Ad‑SIV +
Ad‑Ii‑SIVCErvv
+ MVA‑SIV
CD4+ T‑cells CD8+ T‑cells Antibodies
Gag Env Rev Vif Vpr Gag Env Rev Vif Vpr AUC Titer Avidity
CD4+ T‑cells
Gag
Env 0.046
Rev 0.629 0.015
Vif 0.182 0.223 0.079
Vpr 0.014 0.002 0.074 0.111
CD8+ T‑cells
Gag 0.461 0.496 0.463 0.459 0.862
Env 0.296 0.106 0.256 0.866 0.305 0.081
Rev 0.503 0.777 0.430 0.150 0.307 0.125 0.828
Vif 0.665 0.909 0.748 0.955 0.456 0.911 0.306 0.763
Vpr 0.116 0.480 0.896 1.002 0.082 0.220 0.845 0.144 0.199
Antibodies
AUC 0.075 0.164 0.515 0.477 0.221 0.843 0.230 0.422 0.389 0.853
Titer 0.040 0.157 0.558 0.272 0.085 0.738 0.629 0.725 0.410 0.512 0.004
Avidity 0.053 0.112 0.458 0.346 0.127 0.804 0.601 0.495 0.798 0.798 0.002 0.002
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the breadth of the response, the heterologous immuni-
zation regimen with Ad-Ii-SIVCErvv was clearly supe-
rior to the one without Ad-Ii-SIVCErvv.
In the MVA-boosted group receiving the additional 
Ad-Ii-SIVCErvv prime, Env dominance reappeared and 
slightly more HIVconB Env-specific than HIVconB Gag-
specific CD8+ T-cells were detectable (Fig. 2b). The rea-
son for this reappearance of Env immunodominance is 
not clear, but we speculate that it could result from dif-
ferences in the CD4+ T-cell help. We could assume that 
because Gag/CE-specific CD8+ T-cell responses were 
lower, albeit more cross-reactive, in the Ad-Ii-SIVCErvv 
group compared to the group without Ad-Ii-SIVCErvv, 
they were not able to dominate over and inhibit the 
expansion of HIVconB Env-specific CD8+ T-cells. 
Additionally, CD4+ T-cell responses to the accessory 
antigens, which were not measured in this assay due 
to practical limitations in sample processing, could be 
responsible for the preferred boosting of HIVconB Env 
in the Ad-Ii-SIVCErvv group. Further mechanistic effects 
such as altered T-cell quality rather than quantity, lack 
of IFNγ production in T-cells or induction of regulatory 
T-cells might play a role as well.
In all groups broad antibody responses reacting to Env 
from 2 different HIV-1 clades were elicited and even 
showed some reactivity to SIVmac239 Env (Fig.  3). It is 
striking that we could induce such broadly reactive Env-
binding antibodies that also bind to SIVmac239 Env. Nat-
urally, we cannot be sure if cross-reactive antibodies are 
responsible for this effect or if we instead induced addi-
tional SIVmac239 Env-specific antibodies with the boost. 
HIV-1 Env-targeting monoclonal antibodies with cross-
reactivity to chimpanzee SIV Env have been described 
previously in mice [27]. Therefore, it seems possible that 
we indeed detected HIV-1/SIV cross-reactive antibod-
ies. Additionally, there is a strong positive correlation 
between antibody responses to SIVmac239 and HIV-1 
clade C Env in the group without Ad-Ii-SIVCErvv, which 
could support this assumption (Table 2a).
Antibody responses to HIV-1 clade B, clade C and 
SIVmac239 Env were significantly higher in the Ad-Ii-
SIVCErvv group combined with the MVA boost com-
pared to the boosted group without Ad-Ii-SIVCErvv 
(Fig. 3). This could be explained by the higher numbers 
of Gag/CE-specific CD4+ T-cells in this group providing 
intrastructural help for Env-specific B-cells during the 
boost as previously described for VLP vaccines by Nabi 
et al. [14].
Homologous SIV‑prime SIV‑boost regimen
In the homologous prime-boost regimen CD8+ T-cell 
responses to Env were higher than to Gag in the group 
without Ad-Ii-SIVCErvv 8  months after the boost 
(Fig. 4a). These results differ from the responses observed 
by Andersson and Holst 10  days after the boost [11], 
where stronger Gag- than Env-specific T-cell responses 
were measured. This could most likely be due to differ-
ent kinetics in the Gag- and Env-specific CD8+ T-cell 
responses, with longer expansion and/or greater stability 
of Env-specific CD8+ T-cells.
Adding Ad-Ii-SIVCErvv to the vaccination regi-
men induced higher numbers of Gag- than Env-specific 
CD8+ T-cells (Fig.  4a). Thus, the ratio of Gag- to Env-
specific CD8+ T-cells was significantly higher than in the 
group without Ad-Ii-SIVCErvv. A likely explanation is an 
effect of the encoded CEs since in Andersson and Holst 
broad Gag- and CE-specific CD8+ T-cell responses 
could be induced [11]. In Martins et  al. slightly higher 
Gag- than Env-specific CD8+ T-cell responses were 
observed as well in an immunization regimen including 
Gag, Env, Vif, Rev, Tat, and Nef [17], which would sug-
gest that the accessory antigens might play a role as well 
in this context. In an efficacy model the higher Gag- com-
pared to Env-specific CD8+ T-cell responses in the Ad-
Ii-SIVCErvv group would normally be predicted to result 
in better long-term viral control as CD8+ T-cells target-
ing Gag are correlated with a lower viral load [4, 5] and 
are mediating ex vivo control [28], while T-cell targeting 
of Env is correlated with a higher viral load [4].
In combination with the homologous prime-boost regi-
men Ad-Ii-SIVCErvv induced CD8+ T-cell responses 
to the accessory antigens with a similar pattern as 
the administration of this vector alone (Figs.  1e, 4a). 
Responses to Vpr were the most prominent followed by 
Vif, while in combination with the VLVs even Rev-spe-
cific CD8+ T-cell responses were detectable. The induc-
tion of accessory antigen-specific CD8+ T-cells is likely 
to improve early control of infection as shown in Xu 
et al., Hel et al. and Martins et al. [15, 17, 18].
In the group vaccinated with Ad-Ii-SIVCErvv, Gag- and 
Env-specific CD4+ T-cell responses were lower than in 
the group without Ad-Ii-SIVCErvv, while the responses 
to Rev and Vif were slightly higher (Fig. 4c). It is possible 
that, with the inclusion of the accessory antigens, anti-
gen competition might be responsible for this shift as a 
similar phenomenon was also observed in Hel et al. [18]. 
When a Gag-Pol-Env and a Rev-Tat-Nef vaccine were 
combined, lower T-cell responses to the immunodomi-
nant antigens Gag, Env and Nef were measured com-
pared to the responses to either of the 2 vaccines alone. 
However, Hel et  al. did not distinguish between CD4+ 
and CD8+ T-cells and it was not clear if competition 
between the immunodominant antigens was responsible 
or if the subdominant antigens Rev and Tat played a role.
In the Ad-Ii-SIVCErvv-vaccinated group Env-specific 
CD4+ T-cell responses correlated significantly with 
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Vpr-specific and almost significantly with Rev-specific 
CD4+ T-cells, suggesting that there might be interplay 
between these T-cell specificities (Table  3b). However, 
caution should be taken when interpreting the lower 
CD4+ T-cell responses as animals in the group with-
out Ad-Ii-SIVCErvv occasionally exhibited low CD4+ 
T-cell responses to the accessory antigens after subtrac-
tion of the background values. Nevertheless, whatever 
the mechanism, the observed shift away from the struc-
tural antigens can be considered beneficial as it has been 
shown that CD4+ T-cell responses towards the structural 
antigens are associated with infection-enhancement [19]. 
In addition, CD4+ T-cells specific for Rev and Vif could 
stimulate the expansion of CD8+ T-cells with the same 
specificities and thus help to improve early viral control.
Ad-Ii-SIVCErvv did not influence the antibody 
responses, which were very similar in antibody titer/
AUC, avidity and isotype distribution (Fig. 5).
In both groups more IgG2a and IgG2c than IgG2b and 
no IgG3 antibodies were induced. IgG2b is considered 
more important in the early infection, while IgG2a is 
more associated with antigen clearance through induc-
tion of e.g. antibody-dependent cellular cytotoxicity later 
[29]. However, in our case, the use of IgG2a levels as a 
proxy for antibody effector mechanisms were not very 
informative as the CD1 strain was found to be heteroge-
neous for IgG2a and IgG2c.
Altogether, we found that it was possible to include a 
subdominant antigen vaccine, modified from the one 
described in Xu et al. [15], in a vaccination regimen con-
sisting of dominant antigens with expectedly beneficial 
effects for the T-cell responses in regard to the protec-
tion-associated responses. This effect can be considered 
synergistic as the addition of Ad-Ii-SIVCErvv not only 
raised immune responses to the accessory antigens, but 
also beneficially impacted the T-cell responses to Gag 
and Env.
In Hel et  al. antigen competition could be observed 
when combining dominant and subdominant antigens 
[18]. As we do not have data on the immune response 
to Ad-Ii-SIVCErvv alone 10  months after the immuni-
zation, it is hard to say if the Gag/Env-vaccine impacted 
the T-cell response to the accessory antigens negatively. 
However, in combination with the VLVs we observed 
higher CD8+ T-cell responses to Rev than with the Ad-
Ii-SIVCErvv-vaccination alone (compare Figs.  1e, 4a) 
and the Vpr-specific CD8+ T-cell responses matched 
the Env-specific ones in magnitude. Therefore, it is pos-
sible that the co-administration with the Gag/Env prime 
exerted a positive effect on the response to the accessory 
antigens.
Conclusion
The fully heterologous Gag/Env VLV prime-boost regi-
men was able to overcome the Env immunodominance 
in the CD8+ T-cell responses observed in Andersson 
and Holst, which suggests a more protective response. 
However, the expected increased breadth of Gag-spe-
cific CD8+ T-cell responses was not obtained. In com-
bination with an additional prime encoding SIV Gag 
CEs and accessory antigens, Env dominated the CD8+ 
T-cell response but broader Gag-specific CD8+ T-cell 
responses and higher levels of Env-binding antibodies 
were induced.
The homologous immunization regimen in combina-
tion with Ad-Ii-SIVCErvv was able to improve the induc-
tion of immune responses that have previously been 
correlated with protection against HIV-1 acquisition as 
compared to the VLVs alone. This includes Env-binding 
IgG antibodies, and T-cell responses associated with 
early (accessory antigen-specific CD8+ T-cells) and late 
viral control (more Gag- than Env-specific CD8+ T-cells, 
less Gag/Env-specific CD4+ T-cells). As this seems very 
promising, the next step would be to test this homolo-
gous immunization regimen in a macaque efficacy trial 
using SIVmac251 as the challenge strain.
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Additional file 1. Gating strategy for flow cytometry analysis of intracellu‑
lar cytokine staining. First, the cells were gated for single cells (a) in a side 
scatter (SSC)‑A/SSC‑W plot, which were further gated for the lymphocyte 
population (b) in a plot of forward scatter (FCS)‑A and SSC‑A. The lym‑
phocyte population was gated for CD8+ B220‑ cells (c) and CD4+ B220‑ 
cells (d). Next, these cells were gated for IFNγ+ CD44+ cells (e, upper 
rectangle), here shown representatively for the CD8+ population. From 
these populations the absolute number of IFNγ+ CD44+ B220‑ CD8+ 
and CD4+ T‑cells was calculated by multiplying the percentage of IFNγ+ 
CD44+ B220‑ CD8+/CD4+ cells of the lymphocytes with the number 
of counted lymphocytes per spleen. To obtain the percentage of double 
positive (IFNγ+ TNFα+) cells of IFNγ+ CD8+ and CD4+ T‑cells, CD8+/
CD4+ B220‑ cells were also gated for CD44+ cells (e, both rectangles) in 
homologous prime‑boost regimen and subsequently for IFNγ‑ TNFα+ (f, 
left rectangle) and IFNγ+ TNFα+ (f, right rectangle) cells.
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